Please login to the form below

Not currently logged in
Email:
Password:

vinflunine

This page shows the latest vinflunine news and features for those working in and with pharma, biotech and healthcare.

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

The trial compared Keytruda to the investigator's choice of chemotherapy agents - paclitaxel, docetaxel or vinflunine - and showed that Merck's drug improved both progression-free survival (PFS) and overall survival.

Latest news

  • BMS abandons Pierre Fabre bladder cancer drug

    BMS and Pierre Fabre Medicament terminate their license agreement for the development of metastatic bladder cancer chemotherapy agent, vinflunine. ... US-based Bristol-Myers Squibb and France-headquartered Pierre Fabre Medicament have terminated their

  • Sanofi-aventis and BMS move closer toward merger

    BMS' oncology portfolio is also set to expand, with three oncology drug launches over the next two years: BMS 247550 (ixabepilone), MDX-010 (ipilimumab) and Javlor (vinflunine).

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics